Current interferon alpha-based treatment of hepatitis C virus (HCV) infection fails to cure a sizeable fraction of patients treated. The cause of this treatment failure remains unknown. Here using mathematical modelling, we predict treatment failure to be a consequence of the emergent properties of the interferon-signalling network. HCV induces bistability in the network, creating a new steady ...


 Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents chronic hepatitis C virus infection was efficacious an overall sustained virologic response 12 weeks after near 100%.
 Glecaprevir-pibrentasvir well-tolerated as there were no serious adverse events or leading to discontinuation. Most mild.
 We did not find any studies evaluated t...